Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Short-term Investments (2021 - 2025)

Krystal Biotech's Short-term Investments history spans 5 years, with the latest figure at $331.5 million for Q4 2025.

  • For Q4 2025, Short-term Investments rose 31.2% year-over-year to $331.5 million; the TTM value through Dec 2025 reached $331.5 million, up 31.2%, while the annual FY2025 figure was $331.5 million, 31.2% up from the prior year.
  • Short-term Investments for Q4 2025 was $331.5 million at Krystal Biotech, down from $338.5 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $338.5 million in Q3 2025 and bottomed at $1.2 million in Q1 2021.
  • The 5-year median for Short-term Investments is $207.4 million (2022), against an average of $196.5 million.
  • The largest annual shift saw Short-term Investments soared 13147.52% in 2022 before it decreased 19.98% in 2023.
  • A 5-year view of Short-term Investments shows it stood at $96.8 million in 2021, then soared by 124.34% to $217.3 million in 2022, then fell by 19.98% to $173.8 million in 2023, then soared by 45.33% to $252.7 million in 2024, then skyrocketed by 31.2% to $331.5 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Short-term Investments are $331.5 million (Q4 2025), $338.5 million (Q3 2025), and $328.2 million (Q2 2025).